| Drug ID: | Drug23 |
|---|---|
| Drug Name: | Indomethacin |
| CID: | 3715 |
| DrugBank ID: | DB00328 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05999708 |
| Molecular Formula: | C19H16ClNO4 |
| Molecular Weight: | 357.8 g/mol |
| Isomeric SMILES: | CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O |
| Synonyms: | indomethacin; 53-86-1; indometacin; Indomethacine; Indometacine; Reumacide; Indomethazine; Artrinovo; Confortid; Idomethine |
| Phase 0: | 6 |
| Phase 1: | 22 |
| Phase 2: | 34 |
| Phase 3: | 40 |
| Phase 4: | 33 |
| Description: | Indomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt209 | 3715 | Indomethacin | 2215 | FCGR3B | Homo sapiens (human) | None | |
| dt210 | 3715 | Indomethacin | 133 | ADM | Homo sapiens (human) | None | |
| dt211 | 3715 | Indomethacin | 7442 | TRPV1 | Homo sapiens (human) | None | |
| dt212 | 3715 | Indomethacin | 7298 | TYMS | Homo sapiens (human) | None | |
| dt213 | 3715 | Indomethacin | 4609 | MYC | Homo sapiens (human) | None | |
| dt214 | 3715 | Indomethacin | 10468 | FST | Homo sapiens (human) | None | |
| dt215 | 3715 | Indomethacin | 1636 | ACE | Homo sapiens (human) | None | |
| dt216 | 3715 | Indomethacin | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt217 | 3715 | Indomethacin | 9536 | PTGES | Homo sapiens (human) | None | |
| dt218 | 3715 | Indomethacin | 1576 | CYP3A4 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05999708 | A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants | PHASE1 | WITHDRAWN | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK4381406|DRUG: Placebo|DRUG: Indomethacin | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Ileo-ileal intussusception and necrotising enterocolitis after indomethacin exp…
PMID: 39809488
Year: 2025
Relationship Type:
Association
Score: 6.5
We report a case of small bowel perforation from ileo-ileal intussusception with necrotising enterocolitis (NEC) after indomethacin exposure mimickin…
Sex-specific colonic mitochondrial dysfunction in the indomethacin-induced rat …
PMID: 38595640
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Introduction: Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract and encompasses Crohn's Disease…
Therapeutic effect of bromelain and papain on intestinal injury induced by indo…
PMID: 37692988
Year: 2023
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: Inflammatory bowel diseases (IBDs) are a multiple inflammatory status in small intestines and colon. Bromelain and Papain were cysteine p…
Value of indomethacin suppository for preoperative analgesia and anti-inflammat…
PMID: 37550026
Year: 2023
Relationship Type:
Adverse Effect
Score: 6.5
INTRODUCTION: Postoperative pain has always been a problem for patients and surgeons. Local inflammation, surgical trauma and pain in the body can ca…
Sex-specific colonic mitochondrial dysfunction in the indomethacin-induced infl…
PMID: 36945380
Year: 2023
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract and encompasses Crohn's disease…
Dark-purple rice extract modulates gut microbiota composition in acetic acid- a…
PMID: 36484910
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis (UC) and Crohn's disease (CD) are two major forms of inflammatory bowel disease (IBD). The disease has been linked with gut microb…
Sanguinarine protects against indomethacin-induced small intestine injury in ra…
PMID: 36304153
Year: 2022
Relationship Type:
Treatment
Score: 6.5
In recent years, small intestine as a key target in the treatment of Inflammatory bowel disease caused by NSAIDs has become a hot topic. Sanguinarine…
Cell-free probiotic supernatant (CFS) treatment alleviates indomethacin-induced…
PMID: 35505268
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Probiotics and their metabolites appear to be a promising approach that targets both the intestinal inflammation and dysbiosis in bowel diseases. In …
A quinazoline-based bromodomain inhibitor, CN210, ameliorates indomethacin-indu…
PMID: 34075610
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Inhibitors of bromodomain and extra-terminal motif (BET) proteins are emerging epigenetic therapeutics that suppress gene expressions that drive canc…
Chlorogenic Acid Protects Against Indomethacin-Induced Inflammation and Mucosa …
PMID: 32582202
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Background: Chlorogenic acid (CGA), a natural bioactive polyphenol, exerts anti-inflammatory, antioxidant, and antibacterial effects that support the…
Colon Targeting of Naringin for Enhanced Cytoprotection Against Indomethacin-In…
PMID: 32109993
Year: 2020
Relationship Type:
Association
Score: 6.5
BACKGROUND: Naringin is a promising anti-inflammatory drug against various disorders including ulcerative colitis. However, its oral bioavailability …
Elemental Diet Regulates Intestinal Permeability and Antibody Production in Ind…
PMID: 30814409
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Crohn's disease is a type of inflammatory bowel disease of unknown etiology. Administration of indomethacin (Indo) to rats induces acute mucosal lesi…
Gut Microbiota Mediates Protection Against Enteropathy Induced by Indomethacin
PMID: 28067296
Year: 2017
Relationship Type:
Treatment
Score: 6.3
Non-steroidal anti-inflammatory drugs (NSAIDs) can cause significant small bowel injuries. The role of gut microbiota in this NSAID-induced enteropat…
Effects of Mesalazine on Morphological and Functional Changes in the Indomethac…
PMID: 27294352
Year: 2017
Relationship Type:
Association
Score: 6.3
Morphological and functional changes have been investigated in the rat model of Crohn's disease. The inflammatory bowel disease was induced by indome…
Indomethacin injury to the rat small intestine is dependent upon biliary secret…
PMID: 27033447
Year: 2016
Relationship Type:
Treatment
Score: 6.3
NSAIDuse is limited due to the drugs' toxicity to the gastrointestinal mucosa, an action incompletely understood. Lower gut injury induced byNSAIDs i…
Protective effects of β-casofensin, a bioactive peptide from bovine β-casein, a…
PMID: 26719048
Year: 2016
Relationship Type:
Association
Score: 6.3
SCOPE: beta-casofensin, also known as peptide beta-CN(94-123), is a milk bioactive peptide that modulates the intestinal barrier through its action o…
Orally administered indomethacin acutely reduces cellular prion protein in the …
PMID: 25599123
Year: 2015
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE: The oral uptake of infectious prions represents a common way to acquire a prion disease; thus, host factors, such as gut inflammation and …
Specific changes of gut commensal microbiota and TLRs during indomethacin-induc…
PMID: 24566169
Year: 2014
Relationship Type:
Clinical Trial
Score: 6.3
BACKGROUND AND AIMS: Gut microbiota is a contributing factor in the development and maintenance of intestinal inflammation, although precise cause-ef…
Protective effect of an immune-modulating diet comprising whey peptides and fer…
PMID: 24461940
Year: 2014
Relationship Type:
Association
Score: 6.3
BACKGROUND & AIMS: An immune-modulating diet (IMD) comprising whey peptides and fermented milk products has produced anti-inflammatory effects in var…
Potentiation of indomethacin-induced anti-inflammatory response by montelukast …
PMID: 24338138
Year: 2013
Relationship Type:
Treatment
Score: 6.1
The leukotrienes and prostaglandins are biologically active metabolites derived from arachidonic acid. The leukotrienes have a role in inflammatory d…